BioStem Technologies, Inc. (BSEM)
OTCMKTS: BSEM · Delayed Price · USD
8.85
-0.69 (-7.23%)
Jul 19, 2024, 3:59 PM EDT - Market closed
BioStem Technologies Revenue
BioStem Technologies had revenue of $58.01M in the twelve months ending March 31, 2024, with 1,141.52% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $41.90M with 7,173.74% year-over-year growth. In the year 2023, BioStem Technologies had annual revenue of $16.69M with 142.69% growth.
Revenue (ttm)
$58.01M
Revenue Growth
+1,141.52%
P/S Ratio
2.48
Revenue / Employee
$1,657,529
Employees
35
Market Cap
143.61M
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
Dec 31, 2021 | 4.34M | 1.82M | 72.14% |
Dec 31, 2020 | 2.52M | -108.68K | -4.13% |
Dec 31, 2019 | 2.63M | 1.61M | 158.59% |
Dec 31, 2018 | 1.02M | 688.66K | 209.62% |
Dec 31, 2017 | 328.53K | -263.77K | -44.53% |
Dec 31, 2016 | 592.30K | 440.76K | 290.86% |
Dec 31, 2015 | 151.54K | 120.34K | 385.80% |
Dec 31, 2014 | 31.19K | 15.88K | 103.76% |
Dec 31, 2013 | 15.31K | -791.43K | -98.10% |
Dec 31, 2012 | 806.74K | -556.76K | -40.83% |
Dec 31, 2011 | 1.36M | 101.12K | 8.01% |
Dec 31, 2010 | 1.26M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Eli Lilly | 35.93B |
BSEM News
- 6 days ago - BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments - Newsfile Corp
- 4 weeks ago - UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion - GlobeNewsWire
- 4 weeks ago - PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion - GlobeNewsWire
- 2 months ago - BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts - GlobeNewsWire
- 7 months ago - Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions - GlobeNewsWire
- 11 months ago - NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft - Business Wire
- 11 months ago - NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft - Business Wire
- 11 months ago - BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell - GlobeNewsWire